The clinical effects of anti-angiogenic agents remain controversial. Therefore, elucidating the pharmacological properties of these compounds is a pivotal issue.
Introduction
The pharmacological properties of novel drug candidates are routinely characterized during the preclinical phase of drug development. However, despite the fact that the adsorption, distribution, metabolism and elimination (ADME) of drug compounds can critically influence their therapeutic benefit, in-depth and routine determination of these parameters became the focus of research only in the last decades. Until recently, extensive ADME studies were conducted rather late in the process of drug development, mainly in phase I clinical studies. This may be one of the key factors behind the low, 11%, overall first-in-man to registration rate of novel drug candidates in the 1990s. This proportion was especially poor (5%) among drugs in the field of oncology (Kola and Landis, 2004) .
The vasculature is essential for the maintenance of the necessary oxygen and nutrient supply to malignant cells during tumourigenesis (Dome et al., 2007) . Accordingly, starving the tumour with the inhibition of endothelial growth by anti-angiogenic agents became a widely investigated and applied treatment strategy in the last decade (Waldner and Neurath, 2012) . However, both experimental and clinical results with these drugs are controversial (Amir et al., 2009; Loges et al., 2010; Jayson et al., 2012; Moreno Garcia et al., 2012; Rapisarda and Melillo, 2012; Abe and Kamai, 2013) . Response to treatment often manifests itself as an increase in progression-free survival, but it rarely results in an overall survival benefit (Xiao et al., 2013) . Thus, evaluating the ADME of these agents is a crucial step in drug development. Besides monoclonal antibodies, receptor tyrosine kinase inhibitors (RTKIs) represent the main focus of anti-angiogenic research. Among the RTKIs, sunitinib (SU11248, Sutent ® , Pfizer, New York, NY, USA) is the most widely used in clinical practice. It is a multi-target RTKI, blocking the signalling of the key angiogenic receptors, the VEGF receptors (VEGFRs), the PDGF receptors (PDGFRs) and the FGF receptors (FGFRs) (Mendel et al., 2003; Sun et al., 2003) . Between 2006 and 2011, the Food and Drug Administration approved sunitinib for the treatment of advanced gastrointestinal stromal tumour after disease progression or intolerance to imatinib mesylate (Cananzi et al., 2013) , of advanced renal cell carcinoma (Choueiri, 2013) and also of progressive, undifferentiated, unresectable, locally advanced or metastatic pancreatic neuroendocrine tumour (Peng and Schwarz, 2013) .
The use of MALDI-MS spectroscopic techniques in pharmacological studies dates back to the mid 1990s when in vitro metabolites were characterized by this technique (Chung et al., 1995; Ding et al., 1995; Hooker et al., 1995; Gusev et al., 1996) . The development of matrix-assisted laser desorption ionization MS imaging (MALDI-MSI), as a method to determine the spatial distribution of drugs and their metabolites at histologically relevant resolution, was an important advance in studying drug action (Khatib-Shahidi et al., 2006) . Compared with other methods, which localize drugs in situ, such as autoradiography or PET, MALDI-MSI is label-free and can be applied to native drug structures and their metabolites within any tissue environment. Using this technology, we have recently provided evidence showing the exact tissue compartment localization of low MW drugs administered to patients (Fehniger et al., 2011; Marko-Varga et al., 2012) . To date no imaging data on the distribution of an anti- 
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angiogenic agent has been reported. Taking into consideration that the anti-angiogenic effect on the tumour vessel network may influence the distribution of the antiangiogenic drug itself, such spatial distribution data could greatly help researchers to better understand the mode of action of these agents.
In the current study, we present data on the detection and distribution of sunitinib, its metabolites and its target receptors in normal and tumour tissues of mice bearing C-26 adenocarcinoma, by MALDI-MSI and immunofluorescent imaging respectively. Our results provide the first evidence that MALDI-MSI can be used to conduct ADME studies on low MW anti-angiogenic drugs.
Materials and methods
In vivo tumour model and treatments
All animal care and experimental procedures complied with the animal welfare regulations of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary and were approved by the Institute (permission number: 22.1/722/3/2010). Experiments involving animals are reported in accordance with the ARRIVE guidelines McGrath et al., 2010) . A total of 52 animals were used in the experiments described here.
Female Balb/C mice (10 weeks old) from our colony (National Institute of Oncology, Budapest) were maintained on a daily 12-h light/12-h dark cycle and were housed under pathogen-free conditions in microisolator cages with laboratory chow and water ad libitum. The mouse colon-26 adenocarcinoma cell line [C-26, CLS (Cell Line Service), Mason Research Institute, Eppelheim, Germany] was cultured in RPMI 1640 with 10% FBS and 1% penicillin/streptomycin (all from Sigma-Aldrich, Steinheim, Germany) at 37°C, 5% CO2 in a humidified atmosphere. Groups of five mice were inoculated s.c. with 2 × 10 6 C-26 cells, as described recently (Manea et al., 2011) .
Sunitinib (LC Laboratories, Woburn, MA, USA; CAS. No. 557795-19-4) treatment began 2 weeks after tumour cell injection and was performed once daily at a dose of 100 mg·kg −1 per os with a feeding tube five times a week for 2 weeks. Sunitinib at >99% purity was suspended in 2% carboxymethylcellulose with 2 mg·mL −1 methyl-4-hydroxibenzoate (both from Sigma-Aldrich), while control mice received only the suspending medium. Three hours after the last treatment, peripheral blood was drawn from the canthus and the animals were killed. Tumours, livers and kidneys were removed and snap frozen by submerging the tissues into liquid nitrogen-cooled isopentane, as described previously (Dome et al., 2002) .
Detection of the compound and analysis of drug distribution
A MALDI LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) was used both for compound characterization, drug detection in blood on MALDI target plate and tissue imaging. For compound characterization, drug was dissolved in 50% methanol (MeOH, Sigma-Aldrich) at HPLC grade (>99.8%) at 1 mg·mL −1 stock concentration and stored at 4°C. As matrix 7.5 mg·mL −1 α-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) was dissolved in 50% acetonitrile (ACN; hypergrade for LC-MS; Merck, Darmstadt, Germany) and 50% water, containing 0.1% trifluoroacetic acid (Sigma-Aldrich). One microlitre of the compound solution was applied on the MALDI plate with 1 μL matrix solution. Full mass spectra were obtained using the Fourier transform (FT) analyser (Orbitrap), sampling the spots in a survey mode with positive polarity, collecting 20 experiments in a single run with 60 000 resolution. The nitrogen laser was set to 10 μJ and activated automatic gain control (AGC) was used. For MS/MS experiments the detected precursor ion was fragmentized at normal scan rate, isolating the ions with mass-to-charge ratio (m/z) 1.0 width. The normalized collision energy (NCE) was 40% during an activation time of 30 ms and activation Q of 0.250 was applied in centroid mode.
For detection of the compound in blood, 20 μL of the plasma sample was removed and ACN precipitation was performed. Concentration and elution of the RTKI was implemented with Pierce C18 Tips (Thermo Fisher Scientific, Rockford, IL, USA) following the manufacturer's instructions. One microlitre of the sample was applied on the MALDI plate with 1 μL matrix solution using the same instrument settings as used for the compound characterization.
For tissue drug imaging, 10 μm frozen sections were cut using a cryotome and placed on glass slides. After drying of the tissue, 0.5 mL of the matrix solution was deposited stepwise by an airbrush to avoid wetting. In order to control the spraying conditions, the position of the airbrush was kept constant. Full mass spectra were obtained using the Orbitrap mass analyser at 60 000 resolution (at m/z 400). Tissue sections were sampled in the 150−800 Da mass range in positive mode with 100 μm raster size. The nitrogen laser was operated at 10.0 μJ with AGC on. For MS/MS data collection, the observed sunitinib peak at m/z 399.218 was fragmentized at normal scan rate, with m/z 1.0 width isolation window, using 40% NCE, 30 ms activation time and 0.250 activation Q. The minimal signal required for MS/MS spectra generation by the linear ion trap analyser was 500 counts. Analysis of the spectra was implemented with Xcalibur v 2.0.7. software, while visualization of the drug and fragment ions was performed with the ImageQuest™ software (both from Thermo Fisher Scientific, San José, CA, USA).
Quantification of the precursor compound
For in tissue quantification, calibration curves of the drug compound were established on control tissue sections of tumour, liver and kidney from mice. Sunitinib was dissolved and diluted stepwise in 50% methanol. From each concentration, 0.5 μL was applied onto the tissue surface within the concentration range of 0.00016-2.5 μmol·mL −1 . Spraying and detection conditions were the same as those used for the tissue sample analysis. Calibration curves were created by Quantinetix software (ImaBiotech, Loos, France).
Analysis of target receptor and drug co-localization
For the analysis of target receptor and drug co-localization, five serial frozen sections were cut from each tumour. Section #3 was used to analyse the distribution of the RTKI by MALDI-MSI and for haematoxylin and eosin (HE) staining (Supporting information, Figures S1 and S2). Sections #1-2 and #4-5 were labelled sequentially with either of the following primary antibodies: anti-VEGFR-2 (1:50, Cell Signaling Technology, Danvers, MA, USA; Catalogue number: 55B11), anti-PDGFR-α (1:50, Cell Signaling Technology; Catalogue number: D1E1E), anti-PDGFR-β (1:50, Cell Signaling Technology; Catalogue number: C82A3) or anti-FGFR-1 (1:50, Cell Signaling Technology; Catalogue number: D8E4). All the primary antibodies were labelled with a fluorescent secondary antibody (anti-rabbit Alexa-488, 1:1000, Cell Signaling Technology; Catalogue number: 4412). Nuclei were stained with Hoechst 33342 (Molecular Probes, Eugene, OR, USA) and tumour sections were covered with ProlongGold Antifade Reagent (20 μL, Invitrogen, Carlsbad, CA, USA; Catalogue number: P36930). Slides were scanned by TissueFAXS (TissueGnostics GmbH, Vienna, Austria) and VEGFR-2, PDGFR-α, -β and FGFR-1 expression patterns were analysed by two pathologists (BD and TF).
Data analysis
Statistical analysis was performed to evaluate the in vivo effects of sunitinib. Two diameters of the tumours were measured three times a week and tumour volume was calculated with the formula: width 2 × length × π / 6. Difference between the treated and the control groups in tumour volume and weight was analysed by the Mann-Whitney U-test. Data were considered significant when P ≤ 0.05. Data are based on five independent experiments.
Results
Sunitinib treatment inhibits tumour growth
Syngeneic subcutaneous mouse tumour models are ideal and widely used in translational medicine studies allowing us to evaluate the efficacy of various anticancer agents including anti-angiogenic drugs (Paku et al., 2011; Wong et al., 2012) . Therefore, we decided to compare the effect of sunitinib treatment on tumour development with measures of drug distributions within the tumours. Balb/C mice were injected s.c. with C-26 mouse colon adenocarcinoma cells and 2 weeks later were dosed daily with sunitinib over a 2 week period. Tumours and other tissues were then obtained and analysed. The mean tumour weights in the control and sunitinibtreated groups were 0.274 and 0.090 g respectively ( Figure 1A ; P = 0.0635). More importantly, a 2 week sunitinib treatment resulted in a significant (P = 0.0159) relative tumour growth inhibition as well ( Figure 1B ).
MALDI-MSI identification of sunitinib and its fragment ions
We started our MALD-MSI studies by identifying the monoisotopic mass of pure stock sunitinib compound dried as a droplet at m/z 399.218 (Figure 2A ). Subsequent MS/MS fragmentation of the precursor ions led to the loss of the terminal diethylamino group, generating a fragment ion at m/z 326.1, while the presence of fragment ion at m/z 283.1 indicated a cleavage at the amide group ( Figure 2B ).
Identification of sunitinib and its metabolites in blood
Adsorption of the drug was examined in peripheral blood. Sunitinib was measured in all plasma samples taken just before killing the animals. Moreover, metabolites of the precursor compound were also traceable and could be characterized. Presumed structures and MS/MS spectra of the precursor compound and its metabolites in blood plasma are presented in Figure 3 .
The previously described bis-desethylated metabolite (M1) of sunitinib (Speed et al., 2012) , with a monoisotopic mass at m/z 343.000 could be detected only in a few blood samples performing full mass scans. However, isolating and fragmenting the proposed monoisotopic peak of that metabolite resulted in fragment ions at m/z 326.2 and 283.1 in all samples. Stepwise elevation of the collision energy proved that the detected fragment ions are formed by the fragmentation of M1. The missing precursor ion in full mass spectra may be explained by the low concentration of M1
Figure 1
Sunitinib reduces the in vivo growth of C-26 mouse colon adenocarcinoma cells in Balb/C mice. (A) Tumour weights and (B) percentage of change of tumour volumes of control and sunitinib-treated groups (100% refers to day #1 of the treatments). Data are shown as box (first and third quartiles) and whisker (maximum to minimum) plots with the median (horizontal bar) from 5 animals per group. *P = 0.0635, **P = 0.0159, versus control. that appeared to be below the detection limit of the FT analyser compared with the linear ion trap.
The signal generated at m/z 358.120 of M2 indicates the loss of the terminal diethylamine group, with the oxidation of the molecule. This resulted in a fragment ion at m/z 283.1, but not at m/z 326.1. The presence of fragment ion at m/z 340.2 refers to the terminal dehydroxilation of the molecule.
M3, an active metabolite of sunitinib (SU012662) (Rais et al., 2012) was formed by the mono-desethylation of the molecule, resulting a monoisotopic mass of m/z 371.188 and the same fragment ions as sunitinib.
Two mono-hydroxylated variations of the active metabolite were detected at m/z 387.182. M4 was modified at the indolylidene-dimethylpyrrole moiety, resulting a fragment ion at m/z 299.1. M5 was hydroxylated at the carbon next to the amide nitrogen, which generated a fragment ion at m/z 283.1. The detected fragment ion peak at m/z 369.1 could be derived from both molecules by dehydroxylation, such as m/z 342.2 by the loss of the etylamino group.
Loss of two hydrogen atoms of the terminal ethyl groups of sunitinib generated a metabolite (M6) at m/z 397.202. Fragmentation of the molecule generated ions at m/z 326.1 and 283.1.
Fragment ions of a previously described metabolite with the monoisotopic mass of m/z 397.224 (M7) could also be detected by MS/MS (Speed et al., 2012) . Signals of fragments were generated at m/z 324.2 and 281.2, suggesting defluorination and subsequent dehydroxylation of the molecule. M7 was not traceable by full MS, probably because of the signal suppression of M6 at m/z 397.202.
As with M1, the saturated metabolite of sunitinib, M8, was detected by Speed et al. at m/z 401.00 in rat and monkey faeces (Speed et al., 2012) . This could only be rarely measured in our mouse model by full MS. However, when isolating the presumed metabolite peak, the detected fragment ions at m/z 285.1 and 328.2 indicated the presence of the molecule, and that the saturation occurred at the indolylidenedimethylpyrrole moiety.
Mono-hydroxylated metabolites of sunitinib were also measured at m/z 415.214. Fragmentation of the molecule indicated the oxidation on the indolylidene-dimethylpyrrole group (M9) with 16 Da higher fragments than the corresponding ions of sunitinib at m/z 342.2 and 299.2. Moreover, upon fragmentation of the detected metabolite peak, ions at m/z 326.1 and 283.1 were also formed, indicating that the oxidation occurred either at one of the terminal carbons of the diethylamine group (M10) or at the amine moiety (M11). M11 was previously synthesized as SU012487 (Speed et al., 2012) . Dehydroxylation of any of the mono-hydroxylated metabolites could result in a fragment ion at m/z 397.1.
M12 at m/z 495.283 was identified as a sulphate conjugate of M9. Desulphuration of the molecule gave rise to the fragment ion at m/z 415.2, while dehydroxylation resulted in a fragment ion at m/z 477.3.
The glucuronide metabolite, M13, was detected at m/z 575.252. The cleavage at the amide group and the loss of the terminal diethylamino moiety resulted in fragment ions at 459.2 and 502.2 respectively.
The metabolite at m/z 591.243 (M14) was generated by both the oxidation and the glucuronidation of sunitinib. When the molecule fragmentized as the unmodified compound, ions at m/z 518.2 and 475.1 were generated. Dehydroxylation eventuated in a signal at m/z 573.2, while the fragment ion at m/z 415.2 was formed by the loss of the dehydrated glucuronic acid. Deglucuronidation and dehydroxylation of the molecule resulted in an ion at m/z 342.2.
M3, the active metabolite generated a two-to threefold less-intensive signal than the precursor molecule in blood samples. All the other metabolites were only traceable, with less than 5% of the signal intensity of the unmodified compound (data not shown).
Distribution of administered sunitinib in tumour, liver and kidney tissue sections
The distribution of sunitinib in tumour, liver and kidney tissue samples was examined by MALDI-MSI. The precursor compound with its fragment ions could be detected in all of the tissues mentioned earlier. Representative examples showing the distribution of sunitinib and its fragment ions are shown in Figure 2 . The intratumour localization of the compound was predominantly peripheral, which can either be related to the histological or to the capillary network structures of the tissues. No major intertumour heterogeneity was seen among the sunitinib-treated replicates. Sunitinib and its fragment ions showed co-localization within the tissues. This co-localization can be interpreted as a molecular fingerprint that confirms the identity of sunitinib in these measurements.
We also identified several sunitinib metabolites within the tumour tissue. In particular, the mono-desethylated (m/z 371.188), the desaturated (m/z 397.203), and the monohydroxylated (m/z 415.215) metabolites were observable by imaging (Figure 4) . The precursor compound, its fragment ions and all the measured metabolites showed an overlapping tissue pattern.
Quantification of sunitinib in tumour, liver and kidney tissue samples
Quantification of the drug compound on tissue sections displayed a linear correlation between concentration and signal intensity when normalized to the matrix signal (m/z 379.093). This linearity was found to be between the concentration range of 0.16 nmol·mL −1 and 0.5 μmol·mL −1 in the case of liver and tumour tissues, while it was in the range of 0.16 nmol·mL −1 and 0.1 μmol·mL −1 in the case of kidney sections. The signal intensity of the manually deposited drug solution was the highest from kidney tissue and the lowest from the tumour section. Possible explanations of this phenomenon could be variations in cell density and/or in the physicochemical properties of these tissue types. Calibration curves of sunitinib obtained on tumour, liver and kidney tissue sections are shown in Figure 5 .
Co-localization of drug compound and its target receptors in tumour tissue
The receptor proteins targeted by sunitininb were expressed by C-26 adenocarcinoma cells grown s.c. In these tumour cells, the patterns of expression of these targets was focal for VEGFR-2 or diffuse, for PDGFR-α, PDGFR-β and FGFR-1. Typical patterns of immunofluorescent stainings in frozen tumour tissue samples are shown in Figure 6 . In line with the finding mentioned earlier that drug treatments resulted in significantly slower tumour growth in vivo, we also found reduced intratumour expressions of the key angiogenic receptor VEGFR-2 in sunitinib-treated animals ( Figure 6A ), compared with controls ( Figure 6C ). However, this phenomenon was not accompanied by alterations in the VEGFR-2 staining pattern, which remained focal ( Figure 6A ). It is also important to mention that sunitinib treatments did not affect the expression of PDGF or FGF receptors ( Figure 6A ).
Sunitinib was measured by MALDI-MSI by monitoring the m/z 399.218 ion mass, using 100 μm rastering over the entire tumour cryosection. In Figure 6B , an intensity map is shown, generated by point-by-point sampling, locating the major depots of the drug. In serial sections of sunitinibtreated tumours, the drug distribution as visualized by MALDI-MSI did not show an obvious overlap with the tissue labelling patterns of any of its target receptors. However, composite pictures made from the combination of MALDI-MS and immunofluorescent images identified areas where the highest concentrations of sunitinib were found in the same locations that expressed the highest concentrations of VEGFR-2 ( Figure 6B ). Nevertheless, this latter preliminary observation has to be confirmed by further in-depth studies.
Discussion
Sunitinib is metabolically transformed by cytochrome P450 3A4 (CYP3A4) to its active, desethylated metabolite, SU012662 (M3), which is then further modified by CYP3A4 to inactive forms (Rock et al., 2007) . After administration of a single oral dose, 23-37% of sunitinib is converted to SU012662 in humans (Houk et al., 2010) , underlining the importance of studies evaluating the metabolism of such antitumour drugs in appropriate preclinical settings. Our study confirmed that M3 is the major plasma metabolite present, not only in rats, monkeys and humans, as found by Speed et al. (Speed et al., 2012) , but also in mice. In plasma samples, the signal of this desethylated metabolite was an order of magnitude higher than that of other modified compounds. Although SU012662 generated an order of magnitude lower signal intensity in tissue than sunitinib, this was not necessarily higher than that generated by the other detectable metabolites. This observation can be explained not only by the potential difference in concentration, but also by the different ionizing properties of sunitinib and its derivatives in different tissues.
In the present study, the drug compound and its metabolites were not directly quantified. As the calibration curves we developed for this study showed linear correlation between concentration and signal intensity, such analysis could also be performed by MALDI-MSI by carefully considering the differences of signal intensities originating from different tissues. By preparing calibration curves of synthetic metabolites, accurate studies can be implemented to follow the fate of the original molecule and each of its derivatives in the body.
The observed overlap in the distribution pattern of sunitinib and its metabolites, as detected in the tissue, suggests that the chemical properties responsible for drug dispersion remain similar in the case of the metabolites, and accordingly, that they may contribute to the tumour growth inhibitory activity of the precursor compound as well. Alternatively, the co-localization of sunitinib and its metabolites may indicate that the drug is being taken up and metabolized locally rather than being transported from other sites of metabolism, such as the liver, back to the same location as the precursor drug. Further studies in tissue are warranted to confirm or rule out these assumptions.
Most of the techniques that have analysed sunitinib and its derivatives are based on liquid chromatography coupled with mass spectrometric detection (Baratte et al., 2004; de Bruijn et al., 2010; Zhou and Gallo, 2010; Lankheet et al., 2011; Rodamer et al., 2011; Rais et al., 2012; Speed et al., 2012; Qiu et al., 2013) . However, Etienne-Grimaldi et al. described an HPLC method linked to UV detection of sunitinib and SU12662 in human plasma (Etienne-Grimaldi et al., 2009) . The m/z values of the precursor drug and its derivatives in our study are consistent with these earlier results. The
Figure 6
Intratumour distribution patterns of sunitinib and its target RTKs in sunitinib-treated (A, B) and control (C) mice as visualized by MALDI-MSI and immunofluorescent labelling respectively. In both (A) and (C), the tumours are immunolabelled for VEGFR-2, PDGFR-α, PDGFR-β and FGFR-1 (green). Nuclei are counterstained with Hoechst 33342 (blue). Note the focal (VEGFR-2) and diffuse (PDGFR-α, PDGFR-β, FGFR-1) expression patterns of the tumour cells in both animal groups. Panel B shows an example for coincidence of drug location and targeted receptor in tumour. MALDI-MSI detected sunitinib (m/z 399.218) at high signal intensities in the mantle and in this case in a central area as well. Signal intensity gradients of the drug were seen in discrete compartments throughout the tissue (left picture). In order to investigate the occurrence of cells bearing VEGFR-2 and the distribution of the drug, we first imaged the isolated VEGFR-2 signal from the RGB signal and then overlaid this image with the drug contour map. The highest density of VEGFR-2 bearing cells (red dots) was congruent with the highest concentrations of the drug (right picture). In (A) and (C), the three columns of immunofluorescent pictures (captured by a 20× objective) represent different magnifications of the same image (100, 2000 and 8000%). White rectangles in the lower-power micrographs show the corresponding areas of the higher magnification images.
present study showed that MALDI-MS is also a powerful tool to detect the drug compound ions and its metabolites. The MALDI-MS experimental parts showed a slightly different fragmentation pattern from electrospray ionization-MS (Speed et al., 2012) . Moreover, an advantage of MALDI-MSI compared with other previously used methods is that the earlier techniques require either fluid samples (such as blood or sweat) or the homogenization of the tissue. Therefore, they are not capable of analysing the spatial tissue distribution of a compound in an organ or in a solid tumour.
Although the last half century has witnessed dramatic advances in the field of medical imaging, there is still an urgent need for the development of more advanced techniques for imaging compounds in the drug discovery process. This is particularly important in the narrowing of the selection of potential hits and leads as candidates for further development. One of the reasons this has been difficult to accomplish in the past is that until recently, the only avenue for visualizing the in vivo distribution of drugs in targeted tissues was to use labels, which are commonly radioactive,
Continued. and as such a safety risk. Methods such as PET and autoradiography can provide information on the distribution of a radiolabelled compound, even at the cellular level (Solon et al., 2010; Solon, 2012) . However, both of these methods rely on quantitative data based upon the relative strength of the label rather than the relative concentration of the drug. For these reasons, unlabelled, that is 'cold' compounds will provide evidence that relate to the drug structure only and not to the labelling chemistry in a modified drug molecule. If a drug is metabolized such that the label follows on the fragment that is neither active, nor the precursor of an active form, then the readout of distribution may have little to do with the mode of action or the actual efficacy of the drug (Solon, 2012) . Other methods rely on the use of isotopes with relatively short half-lives or fluorescent tags, which makes long-term pharmacological analysis impossible or alters the chemical structure and thus the binding affinity and/or avidity to its target molecule (Solon et al., 2010) .
From this point of view, it is particularly important that methods be used that investigate the characteristics of the unaltered native compound (i.e. the same agent as that being administered to patients). MS is one such powerful technique, enabling the parallel determination of label-free drugs and their metabolites. The Orbitrap mass analyser in the hybrid instrument used in our study provides very high levels of mass accuracy, to the tens of thousands fraction on a single atomic mass unit (Strupat et al., 2009) . This high accuracy in identification allows strong statistical support for the mass values that we have reported here for sunitinib as either precursor ions, fragment ions, or metabolites formed in situ. The MALDI-MSI technology also allowed label-free identification of this small molecule compound, negating the concern that drug properties could have been altered by the labelling procedure. In principle, MALDI-MSI is not limited to the analysis of low MW compounds, but it might also be suitable for the localization of therapeutic macromolecules, such as peptides (Craik et al., 2013) and antibodies (Glassman and Balthasar, 2014) . In practice, however, the identification of specific antibodies by MALDI-MSI is a challenge as timeof-flight instruments with broad mass range (over m/z 1 million) do not have sufficient resolution at high mass range, while Orbitraps operate up to m/z 4000 (and thus unable to detect singly charged peptides over 4 kDa). Enzymic in situ digestion (Groseclose et al., 2007; Casadonte and Caprioli, 2011; Gustafsson et al., 2013) may provide unique peptides that can help in their precise localization within tissue sections. However, the identification of these peptides is still restricted to matching the accurate precursor masses in MALDI-MS analysis with those observed in an LC-MS/MS experiment used for peptide sequencing.
The current study is the first describing the tissue distribution of an unlabelled anti-angiogenic RTKI and its metabolites by MSI. In our study, the combination of the resolving power of the Orbitrap with the sensitivity of the linear ion trap made it an ideal technique for drug and metabolite detection. We observed that oral administration of sunitinib resulted in a systemic distribution of the drug throughout the body with significant levels being observed in the blood, liver, kidneys and tumour tissue. In this study, we have investigated the patterns of drug distribution in the animals following 2 weeks of daily sunitinib dosing. As such, we have not studied the kinetics of drug accumulation in specific tissue sites, or the kinetics of changes in the biological/ histological makeup of the tumours throughout the course of treatment. We have clearly shown that sunitinib-treated tumours showed areas of higher (typically peripheral) and lower (tumour centre) drug signal intensities rather than a homogeneous dispersal across the entire tumour. Of note, this distribution pattern (i.e. higher signal intensity at the tumour periphery vs. relatively lower levels in the central tumour regions) proved to be reproducible throughout the drug-treated tumour sample replicates. In accordance with the findings of Domingues et al., we observed that VEGFR-2 expression was significantly reduced in treated tumours, compared with untreated ones (Domingues et al., 2011) . The relationship between this reduction and the exposure to the drug cannot be investigated in this study because of a single time point of analysis. However, we can say that the time point represented a window showing a clear biological effect of the drug treatment, as seen by both a reduction in tumour weight and volume.
Today, our understanding of the mode of action and the efficacy of antivascular agents in oncology is especially complex and peculiar. Accordingly, when interpreting our findings, we need to take into consideration that both the tumour tissue levels of sunitininb and the expression pattern of its target receptors vary both spatially and temporally. The actual tumour tissue level of an anticancer drug is always influenced by the global blood supply of the tumour mass and also by local intratumour blood flow changes (i.e. by the distinct vascularization patterns of different intratumour areas as well). Although they also have direct effect against autocrine tumour cell signalling, the main effect of antivascular agents (such as sunitinib) is exerted on the tumour vasculature itself and, consequently, sunitinib influences the efficacy of its own delivery. Additional key background information is that sunitinib binds to its target receptors reversibly and, moreover, that it may also result in significant changes in the expression levels and patterns of its target receptors (Roskoski, 2007) . Our approach can contribute to the elucidation of this complex biology in order to further develop anti-angiogenic treatment strategies.
To the best of our knowledge, the current study provides the first direct evidence that an anti-angiogenic drug given orally is transported to, taken up and metabolized within the targeted compartment, the adenocarcinoma tumour. Moreover, the presented results are the first demonstrating that MALDI-MSI is a versatile and simple method of conducting ADME studies on an anti-angiogenic RTKI. Hence, the current study warrants further investigations to define the precise and optimal role of MALDI-MSI in elucidating the mechanisms of drug action and for validating transport to sites of intended effect. 
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http://dx.doi.org/10.1111/bph.12990 Figure S1 After the MALDI-MSI analysis of tumour tissue sections, the matrix was washed off the slides with 70% ethanol and conventional haematoxylin and eosin (HE) staining was performed. Figure S1 shows the HE-stained section of the sunitinib-treated tumour shown in Figures 6B and C respectively. Figure S2 HE-stained section of the control tumour shown in Figure 6C .
